US2009018068A1PendingUtilityA1
G-protein coupled receptors
Est. expiryDec 10, 2019(expired)· nominal 20-yr term from priority
A61P 9/12A61P 5/18A61P 37/00A61P 9/10A61P 9/14A61P 7/00A61P 7/06A61P 39/00A61P 41/00A61P 3/10A61P 9/00A61P 43/00A61P 9/04A61P 7/10A61P 5/38A61P 25/18A61P 29/00A61P 33/02A61P 31/04A61P 35/00A61P 33/00A61P 3/00A61P 25/22A61P 25/02A61P 25/14A61P 33/14A61P 25/08A61P 25/20A61P 25/00A61P 31/22A61P 31/16A61P 25/04A61P 25/28A61P 3/04A61P 25/16A61P 31/12A61P 31/18A61P 27/02A61P 35/02A61P 19/02A61P 17/00A61P 19/10A61P 1/06A61P 1/00A61P 15/08C07K 14/47A61P 21/04A61P 19/04A61P 17/16A61P 1/16A61P 11/00A61K 38/00A61P 1/10A61P 1/14A61P 1/04A61P 1/08A01K 2217/05A61P 1/02A61P 13/10C07K 14/705A61P 13/08A61P 13/02A61P 21/00A61P 13/12A61P 15/00A61P 19/00A61P 17/06A61P 1/18C07K 14/78A61P 11/06
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host, cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.
Claims
exact text as granted — not AI-modified1 .- 28 . (canceled)
29 . An isolated polypeptide comprising an amino acid sequence having at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 24.
30 . The isolated polypeptide of claim 29 , wherein the polypeptide has leukotriene receptor activity.
31 . An isolated cell expressing the polypeptide of claim 29 .
32 . A method for producing the polypeptide of claim 29 , the method comprising:
(a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide encoding the polypeptide of claim 29 , and (b) recovering the polypeptide so expressed.
33 . A composition comprising the polypeptide of claim 29 and a pharmaceutically acceptable excipient.
34 . A method of screening a compound for effectiveness as an agonist of the polypeptide of claim 29 , the method comprising:
(a) exposing a sample comprising the polypeptide of claim 29 to the compound, and (b) detecting agonist activity in the sample.
35 . A method of screening a compound for effectiveness as an antagonist for the polypeptide of claim 29 , the method comprising:
(a) exposing a sample comprising the polypeptide of claim 29 to the compound, and (b) detecting antagonist activity in the sample.
36 . A method of screening for a compound that specifically binds to the polypeptide of claim 29 , the method comprising:
(a) combining the polypeptide of claim 29 with at least one test compound under suitable conditions, and (b) detecting binding of the polypeptide of claim 29 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 29 .
37 . An antibody that specifically binds to a polypeptide comprising an amino acid sequence of SEQ ID NO: 24.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.